Ixekizumab and newer therapies for plaque psoriasis
Data presented on ixekizumab relating to its fast onset of efficacy, superiority in head-to-head trials, to ustekinumab, guselkumab and adalimumab in psoriatic arthritis
You will learn:
• To understand the impact of psoriasis on a patient’s quality of life (QoL)
• To interpret how to use newer biologics in terms of the pathogenesis of psoriasis
• To evaluate the latest clinical data on the use of ixekizumab (IXE) in order to prioritise patients who will benefit from this newer therapy
WEBINAR HELD ON 30 JANUARY 2023.
To access this module, please register or login: